Skip to content
    Clinical Trials

    SHIVA02 Trial: PFS Ratio Exceeding 1.3 in One-Third of Patients Receiving Matched Therapy

    du Rusquec et alCancer Research Communications

    SHIVA02 Trial: PFS Ratio Exceeding 1.3 in One-Third of Patients Receiving Matched Therapy
    The SHIVA02 trial evaluated a tissue-agnostic precision oncology strategy in patients with refractory solid tumors, using each patient as their own control to compare outcomes on standard-of-care therapy against molecularly targeted therapy guided by a Molecular Biology Board. Tumor responses were monitored prospectively every two months using RECIST 1.1 criteria to calculate the progression-free survival (PFS) ratio (PFS2 on matched therapy divided by PFS1 on standard therapy).
    Among 263 enrolled patients with standard-of-care-refractory cancer, molecular profiling was successfully completed in 192 individuals (73%). However, substantial attrition occurred along the precision medicine pathway, resulting in only 34 patients (13% of the total enrolled population) receiving matched therapy and qualifying for PFS ratio assessment. For this evaluable subset, the median PFS1 on prior standard therapy was 2.1 months (95% CI, 1.8 to 3.6), while the median PFS2 on matched molecular therapy was 2.0 months (95% CI, 1.8 to 2.7).
    A clinically meaningful benefit, defined as a PFS ratio greater than 1.3, was achieved by 11 of the 34 evaluable patients (32%), with 8 patients (24%) reaching a PFS ratio exceeding 1.5. Overall survival was extended in the subgroup able to undergo PFS ratio analysis. Furthermore, ECOG performance status and Royal Marsden Hospital (RMH) prognostic scores significantly impacted overall survival outcomes, underscoring the necessity of stringent patient selection when determining candidacy for molecularly matched regimens in late-stage, refractory malignancies.

    Key Takeaways

    • Among patients receiving matched targeted therapy, 32% (n = 11/34) achieved a PFS ratio exceeding 1.3 and 24% (n = 8/34) exceeded 1.5, with a median PFS2 of 2.0 months (95% CI, 1.8–2.7) compared to a median PFS1 of 2.1 months (95% CI, 1.8–3.6) on prior standard therapy.
    • Across the entire cohort of 263 enrolled refractory cancer patients, molecular profiling was successful in 73% (n = 192), but only 13% (n = 34) ultimately received matched therapy and were eligible for intra-patient control analyses.
    • Overall survival was significantly influenced by baseline ECOG performance status and RMH score, and was prolonged in the subgroup of patients evaluable for PFS ratio analysis.
    Read the original sourceCancer Research Communications